StockData

Cartesian Therapeutics, Inc. (RNAC) stock

RNACNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 1/30
$6.08−0.27 (-4.25%)

Close on Nov 16, 2026Market cap $183.95MP/E –Yield –

Cartesian Therapeutics pe ratio

The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.

Cartesian Therapeutics's pe ratio was 5.1× on Apr 28, 2023.

PE Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2023Apr 28, 20235.1×+1.0
2022Dec 30, 20224.1×–

More Cartesian Therapeutics figures

See a number that looks wrong?